nodes	percent_of_prediction	percent_of_DWPC	metapath
Imipramine—ORM1—Vismodegib—skin cancer	0.158	0.218	CbGbCtD
Imipramine—ORM1—Vemurafenib—skin cancer	0.125	0.172	CbGbCtD
Imipramine—CYP1A2—Imiquimod—skin cancer	0.0574	0.0792	CbGbCtD
Imipramine—CYP2C19—Vismodegib—skin cancer	0.0431	0.0595	CbGbCtD
Imipramine—CYP2E1—Dacarbazine—skin cancer	0.0417	0.0575	CbGbCtD
Imipramine—ABCB1—Vismodegib—skin cancer	0.0348	0.048	CbGbCtD
Imipramine—CYP1A2—Vemurafenib—skin cancer	0.0315	0.0434	CbGbCtD
Imipramine—CYP3A4—Temozolomide—skin cancer	0.0301	0.0415	CbGbCtD
Imipramine—CYP3A4—Imiquimod—skin cancer	0.0301	0.0415	CbGbCtD
Imipramine—CYP2D6—Vemurafenib—skin cancer	0.0259	0.0357	CbGbCtD
Imipramine—CYP1A2—Dacarbazine—skin cancer	0.0241	0.0332	CbGbCtD
Imipramine—CYP3A4—Vismodegib—skin cancer	0.0208	0.0287	CbGbCtD
Imipramine—CYP3A7-CYP3A51P—Docetaxel—skin cancer	0.0193	0.0267	CbGbCtD
Imipramine—CYP3A7—Docetaxel—skin cancer	0.0193	0.0267	CbGbCtD
Imipramine—ABCB1—Dactinomycin—skin cancer	0.0183	0.0252	CbGbCtD
Imipramine—CYP3A4—Vemurafenib—skin cancer	0.0165	0.0227	CbGbCtD
Imipramine—CYP1A2—Fluorouracil—skin cancer	0.0141	0.0195	CbGbCtD
Imipramine—ABCB1—Docetaxel—skin cancer	0.00944	0.013	CbGbCtD
Imipramine—CYP3A4—Docetaxel—skin cancer	0.00565	0.0078	CbGbCtD
Imipramine—CHRM3—muscle of abdomen—skin cancer	0.00504	0.0765	CbGeAlD
Imipramine—HRH1—nose—skin cancer	0.00389	0.0591	CbGeAlD
Imipramine—CHRM5—skin epidermis—skin cancer	0.00329	0.05	CbGeAlD
Imipramine—SLC6A3—nerve—skin cancer	0.00192	0.0291	CbGeAlD
Imipramine—SLC6A2—nerve—skin cancer	0.00155	0.0235	CbGeAlD
Imipramine—HTR2A—hindlimb—skin cancer	0.00153	0.0232	CbGeAlD
Imipramine—HTR7—nerve—skin cancer	0.00149	0.0227	CbGeAlD
Imipramine—DRD2—nerve—skin cancer	0.00141	0.0214	CbGeAlD
Imipramine—HTR2A—appendage—skin cancer	0.00131	0.0199	CbGeAlD
Imipramine—HTR7—endothelium—skin cancer	0.00127	0.0193	CbGeAlD
Imipramine—HTR7—blood vessel—skin cancer	0.00117	0.0178	CbGeAlD
Imipramine—CYP2C18—mammalian vulva—skin cancer	0.00114	0.0173	CbGeAlD
Imipramine—SLC22A4—neck—skin cancer	0.00112	0.0169	CbGeAlD
Imipramine—CHRM5—epithelium—skin cancer	0.00107	0.0163	CbGeAlD
Imipramine—SLC22A3—nipple—skin cancer	0.00103	0.0156	CbGeAlD
Imipramine—KCND2—head—skin cancer	0.00103	0.0156	CbGeAlD
Imipramine—CHRM5—skin of body—skin cancer	0.00102	0.0155	CbGeAlD
Imipramine—ADRA1D—epithelium—skin cancer	0.000959	0.0145	CbGeAlD
Imipramine—HTR2A—nerve—skin cancer	0.000931	0.0141	CbGeAlD
Imipramine—KCND3—head—skin cancer	0.000894	0.0136	CbGeAlD
Imipramine—CHRM4—head—skin cancer	0.000852	0.0129	CbGeAlD
Imipramine—HTR7—neck—skin cancer	0.000839	0.0127	CbGeAlD
Imipramine—HTR2A—endothelium—skin cancer	0.000793	0.012	CbGeAlD
Imipramine—KCNH2—nipple—skin cancer	0.00079	0.012	CbGeAlD
Imipramine—HTR6—head—skin cancer	0.000762	0.0116	CbGeAlD
Imipramine—HTR2A—blood vessel—skin cancer	0.000731	0.0111	CbGeAlD
Imipramine—SLC22A3—connective tissue—skin cancer	0.000728	0.011	CbGeAlD
Imipramine—ADRA1D—female reproductive system—skin cancer	0.000712	0.0108	CbGeAlD
Imipramine—CYP1A2—nipple—skin cancer	0.000676	0.0103	CbGeAlD
Imipramine—CHRM5—head—skin cancer	0.000666	0.0101	CbGeAlD
Imipramine—HRH1—nipple—skin cancer	0.000633	0.00961	CbGeAlD
Imipramine—KCND3—lymph node—skin cancer	0.000626	0.0095	CbGeAlD
Imipramine—ADRA1B—head—skin cancer	0.000608	0.00923	CbGeAlD
Imipramine—HTR7—connective tissue—skin cancer	0.000601	0.00913	CbGeAlD
Imipramine—SLC22A3—mammalian vulva—skin cancer	0.0006	0.0091	CbGeAlD
Imipramine—ADRA1D—head—skin cancer	0.000595	0.00903	CbGeAlD
Imipramine—ORM1—female reproductive system—skin cancer	0.000586	0.0089	CbGeAlD
Imipramine—HTR7—epithelium—skin cancer	0.000571	0.00866	CbGeAlD
Imipramine—SLC22A4—female reproductive system—skin cancer	0.000564	0.00856	CbGeAlD
Imipramine—ADRA1A—epithelium—skin cancer	0.000551	0.00836	CbGeAlD
Imipramine—HTR2C—female reproductive system—skin cancer	0.000527	0.008	CbGeAlD
Imipramine—HTR2A—neck—skin cancer	0.000523	0.00794	CbGeAlD
Imipramine—SLC22A3—female reproductive system—skin cancer	0.000513	0.00779	CbGeAlD
Imipramine—SLC6A4—female reproductive system—skin cancer	0.0005	0.00758	CbGeAlD
Imipramine—CHRM1—female reproductive system—skin cancer	0.000498	0.00756	CbGeAlD
Imipramine—ABCB1—blood vessel—skin cancer	0.000479	0.00727	CbGeAlD
Imipramine—Neuropathy peripheral—Temozolomide—skin cancer	0.000457	0.00248	CcSEcCtD
Imipramine—CHRM2—head—skin cancer	0.000457	0.00693	CbGeAlD
Imipramine—SLC6A3—head—skin cancer	0.000456	0.00691	CbGeAlD
Imipramine—Stomatitis—Temozolomide—skin cancer	0.000455	0.00247	CcSEcCtD
Imipramine—Insomnia—Imiquimod—skin cancer	0.000449	0.00244	CcSEcCtD
Imipramine—HRH1—connective tissue—skin cancer	0.000449	0.00681	CbGeAlD
Imipramine—SLC22A1—head—skin cancer	0.000449	0.00681	CbGeAlD
Imipramine—Paraesthesia—Imiquimod—skin cancer	0.000446	0.00242	CcSEcCtD
Imipramine—CHRM3—female reproductive system—skin cancer	0.000446	0.00676	CbGeAlD
Imipramine—Cardiac failure congestive—Docetaxel—skin cancer	0.000444	0.00241	CcSEcCtD
Imipramine—Somnolence—Imiquimod—skin cancer	0.000441	0.0024	CcSEcCtD
Imipramine—Hepatobiliary disease—Temozolomide—skin cancer	0.000441	0.0024	CcSEcCtD
Imipramine—HTR2C—head—skin cancer	0.00044	0.00668	CbGeAlD
Imipramine—Photosensitivity reaction—Fluorouracil—skin cancer	0.00044	0.00239	CcSEcCtD
Imipramine—SLC6A2—female reproductive system—skin cancer	0.00044	0.00668	CbGeAlD
Imipramine—Alopecia—Bleomycin—skin cancer	0.000439	0.00238	CcSEcCtD
Imipramine—Dyspepsia—Imiquimod—skin cancer	0.000437	0.00237	CcSEcCtD
Imipramine—Decreased appetite—Imiquimod—skin cancer	0.000432	0.00234	CcSEcCtD
Imipramine—Hot flush—Docetaxel—skin cancer	0.00043	0.00234	CcSEcCtD
Imipramine—Infestation NOS—Fluorouracil—skin cancer	0.00043	0.00233	CcSEcCtD
Imipramine—Infestation—Fluorouracil—skin cancer	0.00043	0.00233	CcSEcCtD
Imipramine—Flushing—Dactinomycin—skin cancer	0.00043	0.00233	CcSEcCtD
Imipramine—SLC22A3—head—skin cancer	0.000429	0.00651	CbGeAlD
Imipramine—Gastrointestinal disorder—Imiquimod—skin cancer	0.000429	0.00233	CcSEcCtD
Imipramine—Fatigue—Imiquimod—skin cancer	0.000428	0.00232	CcSEcCtD
Imipramine—Menopausal symptoms—Docetaxel—skin cancer	0.000427	0.00232	CcSEcCtD
Imipramine—HRH1—epithelium—skin cancer	0.000426	0.00647	CbGeAlD
Imipramine—ADRA1A—lymphoid tissue—skin cancer	0.000424	0.00644	CbGeAlD
Imipramine—HTR7—female reproductive system—skin cancer	0.000424	0.00644	CbGeAlD
Imipramine—Acute coronary syndrome—Fluorouracil—skin cancer	0.000424	0.0023	CcSEcCtD
Imipramine—Myocardial infarction—Fluorouracil—skin cancer	0.000421	0.00229	CcSEcCtD
Imipramine—Neuropathy peripheral—Fluorouracil—skin cancer	0.000421	0.00229	CcSEcCtD
Imipramine—Stomatitis—Fluorouracil—skin cancer	0.000419	0.00227	CcSEcCtD
Imipramine—Hepatitis—Temozolomide—skin cancer	0.000419	0.00227	CcSEcCtD
Imipramine—Asthenia—Vemurafenib—skin cancer	0.000418	0.00227	CcSEcCtD
Imipramine—SLC6A4—head—skin cancer	0.000417	0.00634	CbGeAlD
Imipramine—Hypoaesthesia—Temozolomide—skin cancer	0.000417	0.00226	CcSEcCtD
Imipramine—Hallucination—Temozolomide—skin cancer	0.000417	0.00226	CcSEcCtD
Imipramine—CHRM1—head—skin cancer	0.000416	0.00631	CbGeAlD
Imipramine—CYP2B6—skin of body—skin cancer	0.000415	0.0063	CbGeAlD
Imipramine—Urinary tract disorder—Temozolomide—skin cancer	0.000414	0.00225	CcSEcCtD
Imipramine—Cardiac failure—Docetaxel—skin cancer	0.000413	0.00224	CcSEcCtD
Imipramine—Pruritus—Vemurafenib—skin cancer	0.000412	0.00224	CcSEcCtD
Imipramine—Urethral disorder—Temozolomide—skin cancer	0.000411	0.00223	CcSEcCtD
Imipramine—Alopecia—Dactinomycin—skin cancer	0.000409	0.00222	CcSEcCtD
Imipramine—Feeling abnormal—Imiquimod—skin cancer	0.000409	0.00222	CcSEcCtD
Imipramine—Gastrointestinal pain—Imiquimod—skin cancer	0.000406	0.0022	CcSEcCtD
Imipramine—Agranulocytosis—Fluorouracil—skin cancer	0.000401	0.00218	CcSEcCtD
Imipramine—Ill-defined disorder—Bleomycin—skin cancer	0.000401	0.00218	CcSEcCtD
Imipramine—Diarrhoea—Vemurafenib—skin cancer	0.000398	0.00216	CcSEcCtD
Imipramine—KCNH2—female reproductive system—skin cancer	0.000395	0.006	CbGeAlD
Imipramine—Urticaria—Imiquimod—skin cancer	0.000394	0.00214	CcSEcCtD
Imipramine—Abdominal pain—Imiquimod—skin cancer	0.000392	0.00213	CcSEcCtD
Imipramine—Body temperature increased—Imiquimod—skin cancer	0.000392	0.00213	CcSEcCtD
Imipramine—Eye disorder—Temozolomide—skin cancer	0.000391	0.00212	CcSEcCtD
Imipramine—Tinnitus—Temozolomide—skin cancer	0.00039	0.00212	CcSEcCtD
Imipramine—Malaise—Bleomycin—skin cancer	0.00039	0.00212	CcSEcCtD
Imipramine—Cardiac disorder—Temozolomide—skin cancer	0.000389	0.00211	CcSEcCtD
Imipramine—Flushing—Temozolomide—skin cancer	0.000389	0.00211	CcSEcCtD
Imipramine—Leukopenia—Bleomycin—skin cancer	0.000387	0.0021	CcSEcCtD
Imipramine—Dizziness—Vemurafenib—skin cancer	0.000385	0.00209	CcSEcCtD
Imipramine—Hypoaesthesia—Fluorouracil—skin cancer	0.000384	0.00208	CcSEcCtD
Imipramine—Angiopathy—Temozolomide—skin cancer	0.00038	0.00206	CcSEcCtD
Imipramine—Ataxia—Docetaxel—skin cancer	0.000379	0.00206	CcSEcCtD
Imipramine—Immune system disorder—Temozolomide—skin cancer	0.000378	0.00205	CcSEcCtD
Imipramine—Mediastinal disorder—Temozolomide—skin cancer	0.000377	0.00205	CcSEcCtD
Imipramine—HTR2A—connective tissue—skin cancer	0.000375	0.00569	CbGeAlD
Imipramine—Ill-defined disorder—Dactinomycin—skin cancer	0.000374	0.00203	CcSEcCtD
Imipramine—CHRM3—head—skin cancer	0.000372	0.00565	CbGeAlD
Imipramine—Liver function test abnormal—Docetaxel—skin cancer	0.000372	0.00202	CcSEcCtD
Imipramine—HTR1A—head—skin cancer	0.000371	0.00563	CbGeAlD
Imipramine—Vomiting—Vemurafenib—skin cancer	0.00037	0.00201	CcSEcCtD
Imipramine—Alopecia—Temozolomide—skin cancer	0.00037	0.00201	CcSEcCtD
Imipramine—HRH1—mammalian vulva—skin cancer	0.00037	0.00561	CbGeAlD
Imipramine—Orthostatic hypotension—Docetaxel—skin cancer	0.000368	0.002	CcSEcCtD
Imipramine—SLC6A2—head—skin cancer	0.000368	0.00558	CbGeAlD
Imipramine—Rash—Vemurafenib—skin cancer	0.000367	0.00199	CcSEcCtD
Imipramine—Mental disorder—Temozolomide—skin cancer	0.000367	0.00199	CcSEcCtD
Imipramine—Dermatitis—Vemurafenib—skin cancer	0.000367	0.00199	CcSEcCtD
Imipramine—Headache—Vemurafenib—skin cancer	0.000365	0.00198	CcSEcCtD
Imipramine—Malnutrition—Temozolomide—skin cancer	0.000365	0.00198	CcSEcCtD
Imipramine—Breast disorder—Docetaxel—skin cancer	0.000364	0.00198	CcSEcCtD
Imipramine—Discomfort—Bleomycin—skin cancer	0.000364	0.00197	CcSEcCtD
Imipramine—Malaise—Dactinomycin—skin cancer	0.000363	0.00197	CcSEcCtD
Imipramine—Leukopenia—Dactinomycin—skin cancer	0.000361	0.00196	CcSEcCtD
Imipramine—Dysgeusia—Temozolomide—skin cancer	0.000357	0.00194	CcSEcCtD
Imipramine—Asthenia—Imiquimod—skin cancer	0.000356	0.00193	CcSEcCtD
Imipramine—HTR2A—epithelium—skin cancer	0.000356	0.0054	CbGeAlD
Imipramine—Confusional state—Bleomycin—skin cancer	0.000356	0.00193	CcSEcCtD
Imipramine—HTR7—head—skin cancer	0.000354	0.00538	CbGeAlD
Imipramine—Anaphylactic shock—Bleomycin—skin cancer	0.000353	0.00191	CcSEcCtD
Imipramine—Oedema—Bleomycin—skin cancer	0.000353	0.00191	CcSEcCtD
Imipramine—Pruritus—Imiquimod—skin cancer	0.000351	0.00191	CcSEcCtD
Imipramine—Infection—Bleomycin—skin cancer	0.00035	0.0019	CcSEcCtD
Imipramine—Nausea—Vemurafenib—skin cancer	0.000346	0.00188	CcSEcCtD
Imipramine—Thrombocytopenia—Bleomycin—skin cancer	0.000345	0.00187	CcSEcCtD
Imipramine—Arrhythmia—Fluorouracil—skin cancer	0.000345	0.00187	CcSEcCtD
Imipramine—Vision blurred—Temozolomide—skin cancer	0.000344	0.00187	CcSEcCtD
Imipramine—ORM1—lymph node—skin cancer	0.000343	0.00521	CbGeAlD
Imipramine—ADRA1A—head—skin cancer	0.000342	0.00519	CbGeAlD
Imipramine—Tremor—Temozolomide—skin cancer	0.000342	0.00185	CcSEcCtD
Imipramine—Alopecia—Fluorouracil—skin cancer	0.000341	0.00185	CcSEcCtD
Imipramine—Diarrhoea—Imiquimod—skin cancer	0.00034	0.00184	CcSEcCtD
Imipramine—Discomfort—Dactinomycin—skin cancer	0.000339	0.00184	CcSEcCtD
Imipramine—Ill-defined disorder—Temozolomide—skin cancer	0.000338	0.00184	CcSEcCtD
Imipramine—Anorexia—Bleomycin—skin cancer	0.000336	0.00183	CcSEcCtD
Imipramine—CYP2B6—lymphoid tissue—skin cancer	0.000336	0.0051	CbGeAlD
Imipramine—Agitation—Temozolomide—skin cancer	0.000335	0.00182	CcSEcCtD
Imipramine—DRD2—head—skin cancer	0.000335	0.00508	CbGeAlD
Imipramine—Pancytopenia—Docetaxel—skin cancer	0.00033	0.00179	CcSEcCtD
Imipramine—SLC22A4—lymph node—skin cancer	0.00033	0.00501	CbGeAlD
Imipramine—KCNH2—head—skin cancer	0.00033	0.00501	CbGeAlD
Imipramine—Oedema—Dactinomycin—skin cancer	0.000329	0.00179	CcSEcCtD
Imipramine—Malaise—Temozolomide—skin cancer	0.000329	0.00178	CcSEcCtD
Imipramine—Dizziness—Imiquimod—skin cancer	0.000328	0.00178	CcSEcCtD
Imipramine—Infection—Dactinomycin—skin cancer	0.000327	0.00177	CcSEcCtD
Imipramine—Leukopenia—Temozolomide—skin cancer	0.000326	0.00177	CcSEcCtD
Imipramine—CYP2B6—female reproductive system—skin cancer	0.000324	0.00492	CbGeAlD
Imipramine—Palpitations—Temozolomide—skin cancer	0.000322	0.00175	CcSEcCtD
Imipramine—Thrombocytopenia—Dactinomycin—skin cancer	0.000322	0.00175	CcSEcCtD
Imipramine—Paraesthesia—Bleomycin—skin cancer	0.000317	0.00172	CcSEcCtD
Imipramine—Weight increased—Docetaxel—skin cancer	0.000317	0.00172	CcSEcCtD
Imipramine—HRH1—female reproductive system—skin cancer	0.000317	0.00481	CbGeAlD
Imipramine—Vision blurred—Fluorouracil—skin cancer	0.000317	0.00172	CcSEcCtD
Imipramine—Convulsion—Temozolomide—skin cancer	0.000316	0.00171	CcSEcCtD
Imipramine—Vomiting—Imiquimod—skin cancer	0.000316	0.00171	CcSEcCtD
Imipramine—CYP2E1—lymphoid tissue—skin cancer	0.000315	0.00479	CbGeAlD
Imipramine—Weight decreased—Docetaxel—skin cancer	0.000315	0.00171	CcSEcCtD
Imipramine—Hypertension—Temozolomide—skin cancer	0.000315	0.00171	CcSEcCtD
Imipramine—Anorexia—Dactinomycin—skin cancer	0.000314	0.0017	CcSEcCtD
Imipramine—Rash—Imiquimod—skin cancer	0.000313	0.0017	CcSEcCtD
Imipramine—Dermatitis—Imiquimod—skin cancer	0.000313	0.0017	CcSEcCtD
Imipramine—Headache—Imiquimod—skin cancer	0.000311	0.00169	CcSEcCtD
Imipramine—Infestation—Docetaxel—skin cancer	0.00031	0.00168	CcSEcCtD
Imipramine—Infestation NOS—Docetaxel—skin cancer	0.00031	0.00168	CcSEcCtD
Imipramine—Anxiety—Temozolomide—skin cancer	0.000309	0.00168	CcSEcCtD
Imipramine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000308	0.00167	CcSEcCtD
Imipramine—Discomfort—Temozolomide—skin cancer	0.000307	0.00166	CcSEcCtD
Imipramine—Decreased appetite—Bleomycin—skin cancer	0.000307	0.00166	CcSEcCtD
Imipramine—Acute coronary syndrome—Docetaxel—skin cancer	0.000306	0.00166	CcSEcCtD
Imipramine—CYP2E1—female reproductive system—skin cancer	0.000304	0.00462	CbGeAlD
Imipramine—Myocardial infarction—Docetaxel—skin cancer	0.000304	0.00165	CcSEcCtD
Imipramine—Neuropathy peripheral—Docetaxel—skin cancer	0.000304	0.00165	CcSEcCtD
Imipramine—Dry mouth—Temozolomide—skin cancer	0.000304	0.00165	CcSEcCtD
Imipramine—Jaundice—Docetaxel—skin cancer	0.000302	0.00164	CcSEcCtD
Imipramine—Stomatitis—Docetaxel—skin cancer	0.000302	0.00164	CcSEcCtD
Imipramine—Leukopenia—Fluorouracil—skin cancer	0.000301	0.00163	CcSEcCtD
Imipramine—SLC22A3—lymph node—skin cancer	0.0003	0.00456	CbGeAlD
Imipramine—Confusional state—Temozolomide—skin cancer	0.0003	0.00163	CcSEcCtD
Imipramine—Anaphylactic shock—Temozolomide—skin cancer	0.000298	0.00162	CcSEcCtD
Imipramine—Oedema—Temozolomide—skin cancer	0.000298	0.00162	CcSEcCtD
Imipramine—Infection—Temozolomide—skin cancer	0.000296	0.0016	CcSEcCtD
Imipramine—Nausea—Imiquimod—skin cancer	0.000295	0.0016	CcSEcCtD
Imipramine—Hepatobiliary disease—Docetaxel—skin cancer	0.000293	0.00159	CcSEcCtD
Imipramine—Nervous system disorder—Temozolomide—skin cancer	0.000292	0.00158	CcSEcCtD
Imipramine—Thrombocytopenia—Temozolomide—skin cancer	0.000291	0.00158	CcSEcCtD
Imipramine—Convulsion—Fluorouracil—skin cancer	0.000291	0.00158	CcSEcCtD
Imipramine—Feeling abnormal—Bleomycin—skin cancer	0.000291	0.00158	CcSEcCtD
Imipramine—Agranulocytosis—Docetaxel—skin cancer	0.00029	0.00157	CcSEcCtD
Imipramine—Skin disorder—Temozolomide—skin cancer	0.000289	0.00157	CcSEcCtD
Imipramine—Hyperhidrosis—Temozolomide—skin cancer	0.000288	0.00156	CcSEcCtD
Imipramine—Decreased appetite—Dactinomycin—skin cancer	0.000286	0.00155	CcSEcCtD
Imipramine—Fatigue—Dactinomycin—skin cancer	0.000284	0.00154	CcSEcCtD
Imipramine—Anorexia—Temozolomide—skin cancer	0.000284	0.00154	CcSEcCtD
Imipramine—Discomfort—Fluorouracil—skin cancer	0.000283	0.00153	CcSEcCtD
Imipramine—Urticaria—Bleomycin—skin cancer	0.00028	0.00152	CcSEcCtD
Imipramine—Body temperature increased—Bleomycin—skin cancer	0.000279	0.00151	CcSEcCtD
Imipramine—Hepatitis—Docetaxel—skin cancer	0.000279	0.00151	CcSEcCtD
Imipramine—Hypoaesthesia—Docetaxel—skin cancer	0.000277	0.0015	CcSEcCtD
Imipramine—Confusional state—Fluorouracil—skin cancer	0.000276	0.0015	CcSEcCtD
Imipramine—Urinary tract disorder—Docetaxel—skin cancer	0.000275	0.00149	CcSEcCtD
Imipramine—Anaphylactic shock—Fluorouracil—skin cancer	0.000274	0.00149	CcSEcCtD
Imipramine—Oedema—Fluorouracil—skin cancer	0.000274	0.00149	CcSEcCtD
Imipramine—Urethral disorder—Docetaxel—skin cancer	0.000273	0.00148	CcSEcCtD
Imipramine—Infection—Fluorouracil—skin cancer	0.000272	0.00148	CcSEcCtD
Imipramine—Feeling abnormal—Dactinomycin—skin cancer	0.000271	0.00147	CcSEcCtD
Imipramine—CYP2B6—head—skin cancer	0.000271	0.00411	CbGeAlD
Imipramine—Insomnia—Temozolomide—skin cancer	0.000269	0.00146	CcSEcCtD
Imipramine—Gastrointestinal pain—Dactinomycin—skin cancer	0.000269	0.00146	CcSEcCtD
Imipramine—Nervous system disorder—Fluorouracil—skin cancer	0.000269	0.00146	CcSEcCtD
Imipramine—Thrombocytopenia—Fluorouracil—skin cancer	0.000268	0.00146	CcSEcCtD
Imipramine—Tachycardia—Fluorouracil—skin cancer	0.000268	0.00145	CcSEcCtD
Imipramine—Paraesthesia—Temozolomide—skin cancer	0.000267	0.00145	CcSEcCtD
Imipramine—Somnolence—Temozolomide—skin cancer	0.000265	0.00144	CcSEcCtD
Imipramine—HRH1—head—skin cancer	0.000265	0.00401	CbGeAlD
Imipramine—HTR2A—female reproductive system—skin cancer	0.000264	0.00401	CbGeAlD
Imipramine—Dyspepsia—Temozolomide—skin cancer	0.000262	0.00142	CcSEcCtD
Imipramine—Anorexia—Fluorouracil—skin cancer	0.000261	0.00142	CcSEcCtD
Imipramine—Eye disorder—Docetaxel—skin cancer	0.00026	0.00141	CcSEcCtD
Imipramine—Body temperature increased—Dactinomycin—skin cancer	0.00026	0.00141	CcSEcCtD
Imipramine—Abdominal pain—Dactinomycin—skin cancer	0.00026	0.00141	CcSEcCtD
Imipramine—Decreased appetite—Temozolomide—skin cancer	0.000259	0.0014	CcSEcCtD
Imipramine—Cardiac disorder—Docetaxel—skin cancer	0.000258	0.0014	CcSEcCtD
Imipramine—Flushing—Docetaxel—skin cancer	0.000258	0.0014	CcSEcCtD
Imipramine—SLC6A2—lymph node—skin cancer	0.000257	0.00391	CbGeAlD
Imipramine—Gastrointestinal disorder—Temozolomide—skin cancer	0.000257	0.00139	CcSEcCtD
Imipramine—Fatigue—Temozolomide—skin cancer	0.000257	0.00139	CcSEcCtD
Imipramine—Constipation—Temozolomide—skin cancer	0.000254	0.00138	CcSEcCtD
Imipramine—CYP2E1—head—skin cancer	0.000254	0.00386	CbGeAlD
Imipramine—Asthenia—Bleomycin—skin cancer	0.000253	0.00137	CcSEcCtD
Imipramine—Angiopathy—Docetaxel—skin cancer	0.000253	0.00137	CcSEcCtD
Imipramine—Immune system disorder—Docetaxel—skin cancer	0.000252	0.00137	CcSEcCtD
Imipramine—Mediastinal disorder—Docetaxel—skin cancer	0.000251	0.00136	CcSEcCtD
Imipramine—Pruritus—Bleomycin—skin cancer	0.00025	0.00135	CcSEcCtD
Imipramine—Arrhythmia—Docetaxel—skin cancer	0.000249	0.00135	CcSEcCtD
Imipramine—Insomnia—Fluorouracil—skin cancer	0.000248	0.00135	CcSEcCtD
Imipramine—Paraesthesia—Fluorouracil—skin cancer	0.000246	0.00134	CcSEcCtD
Imipramine—Alopecia—Docetaxel—skin cancer	0.000246	0.00134	CcSEcCtD
Imipramine—Feeling abnormal—Temozolomide—skin cancer	0.000245	0.00133	CcSEcCtD
Imipramine—CYP3A4—female reproductive system—skin cancer	0.000245	0.00372	CbGeAlD
Imipramine—Mental disorder—Docetaxel—skin cancer	0.000244	0.00132	CcSEcCtD
Imipramine—Somnolence—Fluorouracil—skin cancer	0.000244	0.00132	CcSEcCtD
Imipramine—Gastrointestinal pain—Temozolomide—skin cancer	0.000243	0.00132	CcSEcCtD
Imipramine—Malnutrition—Docetaxel—skin cancer	0.000242	0.00132	CcSEcCtD
Imipramine—Dyspepsia—Fluorouracil—skin cancer	0.000241	0.00131	CcSEcCtD
Imipramine—CYP2D6—female reproductive system—skin cancer	0.000241	0.00366	CbGeAlD
Imipramine—Decreased appetite—Fluorouracil—skin cancer	0.000238	0.00129	CcSEcCtD
Imipramine—Dysgeusia—Docetaxel—skin cancer	0.000237	0.00129	CcSEcCtD
Imipramine—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000237	0.00128	CcSEcCtD
Imipramine—Urticaria—Temozolomide—skin cancer	0.000236	0.00128	CcSEcCtD
Imipramine—Asthenia—Dactinomycin—skin cancer	0.000236	0.00128	CcSEcCtD
Imipramine—Abdominal pain—Temozolomide—skin cancer	0.000235	0.00128	CcSEcCtD
Imipramine—Body temperature increased—Temozolomide—skin cancer	0.000235	0.00128	CcSEcCtD
Imipramine—ABCB1—epithelium—skin cancer	0.000233	0.00354	CbGeAlD
Imipramine—KCNH2—lymph node—skin cancer	0.000231	0.00351	CbGeAlD
Imipramine—Feeling abnormal—Fluorouracil—skin cancer	0.000226	0.00123	CcSEcCtD
Imipramine—Diarrhoea—Dactinomycin—skin cancer	0.000225	0.00122	CcSEcCtD
Imipramine—Vomiting—Bleomycin—skin cancer	0.000224	0.00122	CcSEcCtD
Imipramine—Rash—Bleomycin—skin cancer	0.000222	0.00121	CcSEcCtD
Imipramine—Dermatitis—Bleomycin—skin cancer	0.000222	0.00121	CcSEcCtD
Imipramine—HTR2A—head—skin cancer	0.000221	0.00335	CbGeAlD
Imipramine—Urticaria—Fluorouracil—skin cancer	0.000218	0.00118	CcSEcCtD
Imipramine—Syncope—Docetaxel—skin cancer	0.000217	0.00118	CcSEcCtD
Imipramine—Leukopenia—Docetaxel—skin cancer	0.000217	0.00118	CcSEcCtD
Imipramine—Body temperature increased—Fluorouracil—skin cancer	0.000217	0.00118	CcSEcCtD
Imipramine—Palpitations—Docetaxel—skin cancer	0.000214	0.00116	CcSEcCtD
Imipramine—Asthenia—Temozolomide—skin cancer	0.000213	0.00116	CcSEcCtD
Imipramine—Loss of consciousness—Docetaxel—skin cancer	0.000213	0.00116	CcSEcCtD
Imipramine—Pruritus—Temozolomide—skin cancer	0.000211	0.00114	CcSEcCtD
Imipramine—Convulsion—Docetaxel—skin cancer	0.00021	0.00114	CcSEcCtD
Imipramine—Nausea—Bleomycin—skin cancer	0.00021	0.00114	CcSEcCtD
Imipramine—Hypertension—Docetaxel—skin cancer	0.000209	0.00114	CcSEcCtD
Imipramine—Vomiting—Dactinomycin—skin cancer	0.000209	0.00114	CcSEcCtD
Imipramine—Rash—Dactinomycin—skin cancer	0.000207	0.00113	CcSEcCtD
Imipramine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000205	0.00111	CcSEcCtD
Imipramine—Diarrhoea—Temozolomide—skin cancer	0.000204	0.00111	CcSEcCtD
Imipramine—ABCB1—mammalian vulva—skin cancer	0.000202	0.00307	CbGeAlD
Imipramine—Dry mouth—Docetaxel—skin cancer	0.000202	0.0011	CcSEcCtD
Imipramine—CYP2D6—head—skin cancer	0.000201	0.00305	CbGeAlD
Imipramine—Confusional state—Docetaxel—skin cancer	0.0002	0.00108	CcSEcCtD
Imipramine—Anaphylactic shock—Docetaxel—skin cancer	0.000198	0.00107	CcSEcCtD
Imipramine—Oedema—Docetaxel—skin cancer	0.000198	0.00107	CcSEcCtD
Imipramine—Dizziness—Temozolomide—skin cancer	0.000197	0.00107	CcSEcCtD
Imipramine—Infection—Docetaxel—skin cancer	0.000197	0.00107	CcSEcCtD
Imipramine—Nausea—Dactinomycin—skin cancer	0.000195	0.00106	CcSEcCtD
Imipramine—Shock—Docetaxel—skin cancer	0.000195	0.00106	CcSEcCtD
Imipramine—Nervous system disorder—Docetaxel—skin cancer	0.000194	0.00105	CcSEcCtD
Imipramine—Pruritus—Fluorouracil—skin cancer	0.000194	0.00105	CcSEcCtD
Imipramine—Thrombocytopenia—Docetaxel—skin cancer	0.000194	0.00105	CcSEcCtD
Imipramine—Tachycardia—Docetaxel—skin cancer	0.000193	0.00105	CcSEcCtD
Imipramine—Skin disorder—Docetaxel—skin cancer	0.000192	0.00104	CcSEcCtD
Imipramine—Vomiting—Temozolomide—skin cancer	0.000189	0.00103	CcSEcCtD
Imipramine—Anorexia—Docetaxel—skin cancer	0.000189	0.00102	CcSEcCtD
Imipramine—Rash—Temozolomide—skin cancer	0.000188	0.00102	CcSEcCtD
Imipramine—Diarrhoea—Fluorouracil—skin cancer	0.000188	0.00102	CcSEcCtD
Imipramine—Dermatitis—Temozolomide—skin cancer	0.000187	0.00102	CcSEcCtD
Imipramine—Headache—Temozolomide—skin cancer	0.000186	0.00101	CcSEcCtD
Imipramine—HRH1—lymph node—skin cancer	0.000185	0.00281	CbGeAlD
Imipramine—Dizziness—Fluorouracil—skin cancer	0.000181	0.000984	CcSEcCtD
Imipramine—ABCB1—lymphoid tissue—skin cancer	0.00018	0.00273	CbGeAlD
Imipramine—Insomnia—Docetaxel—skin cancer	0.000179	0.000972	CcSEcCtD
Imipramine—Paraesthesia—Docetaxel—skin cancer	0.000178	0.000965	CcSEcCtD
Imipramine—Nausea—Temozolomide—skin cancer	0.000177	0.000959	CcSEcCtD
Imipramine—Somnolence—Docetaxel—skin cancer	0.000176	0.000955	CcSEcCtD
Imipramine—Vomiting—Fluorouracil—skin cancer	0.000174	0.000946	CcSEcCtD
Imipramine—Dyspepsia—Docetaxel—skin cancer	0.000174	0.000946	CcSEcCtD
Imipramine—ABCB1—female reproductive system—skin cancer	0.000173	0.00263	CbGeAlD
Imipramine—Rash—Fluorouracil—skin cancer	0.000173	0.000938	CcSEcCtD
Imipramine—Dermatitis—Fluorouracil—skin cancer	0.000173	0.000938	CcSEcCtD
Imipramine—Decreased appetite—Docetaxel—skin cancer	0.000172	0.000934	CcSEcCtD
Imipramine—Headache—Fluorouracil—skin cancer	0.000172	0.000932	CcSEcCtD
Imipramine—Gastrointestinal disorder—Docetaxel—skin cancer	0.000171	0.000927	CcSEcCtD
Imipramine—Fatigue—Docetaxel—skin cancer	0.000171	0.000926	CcSEcCtD
Imipramine—Constipation—Docetaxel—skin cancer	0.000169	0.000919	CcSEcCtD
Imipramine—Feeling abnormal—Docetaxel—skin cancer	0.000163	0.000885	CcSEcCtD
Imipramine—Nausea—Fluorouracil—skin cancer	0.000163	0.000884	CcSEcCtD
Imipramine—Gastrointestinal pain—Docetaxel—skin cancer	0.000162	0.000878	CcSEcCtD
Imipramine—Body temperature increased—Docetaxel—skin cancer	0.000156	0.000849	CcSEcCtD
Imipramine—Abdominal pain—Docetaxel—skin cancer	0.000156	0.000849	CcSEcCtD
Imipramine—ABCB1—head—skin cancer	0.000145	0.0022	CbGeAlD
Imipramine—Asthenia—Docetaxel—skin cancer	0.000142	0.000771	CcSEcCtD
Imipramine—Pruritus—Docetaxel—skin cancer	0.00014	0.00076	CcSEcCtD
Imipramine—Diarrhoea—Docetaxel—skin cancer	0.000135	0.000735	CcSEcCtD
Imipramine—Dizziness—Docetaxel—skin cancer	0.000131	0.00071	CcSEcCtD
Imipramine—Vomiting—Docetaxel—skin cancer	0.000126	0.000683	CcSEcCtD
Imipramine—Rash—Docetaxel—skin cancer	0.000125	0.000677	CcSEcCtD
Imipramine—Dermatitis—Docetaxel—skin cancer	0.000125	0.000677	CcSEcCtD
Imipramine—Headache—Docetaxel—skin cancer	0.000124	0.000673	CcSEcCtD
Imipramine—Nausea—Docetaxel—skin cancer	0.000118	0.000638	CcSEcCtD
Imipramine—ABCB1—lymph node—skin cancer	0.000101	0.00154	CbGeAlD
Imipramine—CYP2B6—Metabolism—ENO2—skin cancer	9.48e-06	0.000384	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—PTGER4—skin cancer	9.46e-06	0.000383	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—SHH—skin cancer	9.45e-06	0.000382	CbGpPWpGaD
Imipramine—SLC22A1—Neuronal System—HRAS—skin cancer	9.39e-06	0.00038	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—RASA1—skin cancer	9.39e-06	0.00038	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—SHH—skin cancer	9.29e-06	0.000376	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—ENO2—skin cancer	9.29e-06	0.000376	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—SHH—skin cancer	9.27e-06	0.000376	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—SHH—skin cancer	9.24e-06	0.000374	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—RASA1—skin cancer	9.24e-06	0.000374	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—RASA1—skin cancer	9.22e-06	0.000373	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—SHH—skin cancer	9.22e-06	0.000373	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—RASA1—skin cancer	9.19e-06	0.000372	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—RASA1—skin cancer	9.16e-06	0.000371	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—SHH—skin cancer	9.13e-06	0.00037	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—SHH—skin cancer	9.1e-06	0.000368	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—RASA1—skin cancer	9.07e-06	0.000367	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—RASA1—skin cancer	9.04e-06	0.000366	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—SMO—skin cancer	8.95e-06	0.000363	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—PTCH1—skin cancer	8.95e-06	0.000363	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—SMO—skin cancer	8.81e-06	0.000357	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—PTCH1—skin cancer	8.81e-06	0.000357	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—PTCH1—skin cancer	8.79e-06	0.000356	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—SMO—skin cancer	8.79e-06	0.000356	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—FOXO4—skin cancer	8.77e-06	0.000355	CbGpPWpGaD
Imipramine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	8.77e-06	0.000355	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—PTCH1—skin cancer	8.76e-06	0.000355	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—SMO—skin cancer	8.76e-06	0.000355	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—PTCH1—skin cancer	8.74e-06	0.000354	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—SMO—skin cancer	8.74e-06	0.000354	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—FOXO4—skin cancer	8.73e-06	0.000353	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—PTGER4—skin cancer	8.72e-06	0.000353	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—PTCH1—skin cancer	8.65e-06	0.00035	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—SMO—skin cancer	8.65e-06	0.00035	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—PTCH1—skin cancer	8.63e-06	0.000349	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—SMO—skin cancer	8.63e-06	0.000349	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—PTGER4—skin cancer	8.58e-06	0.000347	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—PTGER4—skin cancer	8.56e-06	0.000347	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—PTGER4—skin cancer	8.53e-06	0.000345	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—PTGER4—skin cancer	8.5e-06	0.000344	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—PTGER4—skin cancer	8.42e-06	0.000341	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—PTGER4—skin cancer	8.4e-06	0.00034	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—FOXO4—skin cancer	8.35e-06	0.000338	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—CSPG4—skin cancer	8.21e-06	0.000333	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—TERT—skin cancer	7.91e-06	0.00032	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—TERT—skin cancer	7.9e-06	0.00032	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PLIN2—skin cancer	7.86e-06	0.000318	CbGpPWpGaD
Imipramine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	7.8e-06	0.000316	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—FOXO4—skin cancer	7.7e-06	0.000312	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—FOXO4—skin cancer	7.58e-06	0.000307	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—FOXO4—skin cancer	7.56e-06	0.000306	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—FOXO4—skin cancer	7.54e-06	0.000305	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—FOXO4—skin cancer	7.51e-06	0.000304	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—TERT—skin cancer	7.47e-06	0.000302	CbGpPWpGaD
Imipramine—CYP3A7—Metabolism—ERCC2—skin cancer	7.45e-06	0.000302	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—FOXO4—skin cancer	7.44e-06	0.000301	CbGpPWpGaD
Imipramine—SLC22A2—Metabolism—ERCC2—skin cancer	7.44e-06	0.000301	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—FOXO4—skin cancer	7.42e-06	0.0003	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—ENO2—skin cancer	7.16e-06	0.00029	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—TERT—skin cancer	7.15e-06	0.000289	CbGpPWpGaD
Imipramine—SLC22A3—Metabolism—PTGS2—skin cancer	7.11e-06	0.000288	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—ENO2—skin cancer	6.99e-06	0.000283	CbGpPWpGaD
Imipramine—SLC22A1—Metabolism—ERCC2—skin cancer	6.93e-06	0.000281	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—TERT—skin cancer	6.72e-06	0.000272	CbGpPWpGaD
Imipramine—CYP2C18—Metabolism—PTGS2—skin cancer	6.72e-06	0.000272	CbGpPWpGaD
Imipramine—HTR6—Signaling by GPCR—NRAS—skin cancer	6.67e-06	0.00027	CbGpPWpGaD
Imipramine—HTR7—Signaling by GPCR—NRAS—skin cancer	6.66e-06	0.00027	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—ENO2—skin cancer	6.59e-06	0.000267	CbGpPWpGaD
Imipramine—CHRM3—Metabolism—ERCC2—skin cancer	6.4e-06	0.000259	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—CSPG4—skin cancer	6.34e-06	0.000257	CbGpPWpGaD
Imipramine—CHRM4—Signaling by GPCR—NRAS—skin cancer	6.29e-06	0.000255	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—BRAF—skin cancer	6.27e-06	0.000254	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—BRAF—skin cancer	6.26e-06	0.000253	CbGpPWpGaD
Imipramine—CHRM5—Signaling by GPCR—NRAS—skin cancer	6.02e-06	0.000244	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—BRAF—skin cancer	5.91e-06	0.000239	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—TERT—skin cancer	5.86e-06	0.000237	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—TERT—skin cancer	5.83e-06	0.000236	CbGpPWpGaD
Imipramine—HTR6—Signaling by GPCR—KRAS—skin cancer	5.74e-06	0.000232	CbGpPWpGaD
Imipramine—HTR7—Signaling by GPCR—KRAS—skin cancer	5.73e-06	0.000232	CbGpPWpGaD
Imipramine—ADRA1D—Signaling by GPCR—NRAS—skin cancer	5.66e-06	0.000229	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—BRAF—skin cancer	5.66e-06	0.000229	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	5.6e-06	0.000227	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—ENO2—skin cancer	5.58e-06	0.000226	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—TERT—skin cancer	5.58e-06	0.000226	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—ERCC2—skin cancer	5.51e-06	0.000223	CbGpPWpGaD
Imipramine—CHRM4—Signaling by GPCR—KRAS—skin cancer	5.41e-06	0.000219	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—ERCC2—skin cancer	5.39e-06	0.000218	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—BRAF—skin cancer	5.32e-06	0.000216	CbGpPWpGaD
Imipramine—CHRM5—Signaling by GPCR—KRAS—skin cancer	5.18e-06	0.00021	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—TERT—skin cancer	5.14e-06	0.000208	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—TERT—skin cancer	5.06e-06	0.000205	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—TERT—skin cancer	5.05e-06	0.000204	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—TERT—skin cancer	5.03e-06	0.000204	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—TERT—skin cancer	5.02e-06	0.000203	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—TERT—skin cancer	4.97e-06	0.000201	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—TERT—skin cancer	4.96e-06	0.000201	CbGpPWpGaD
Imipramine—HTR1A—Signaling by GPCR—NRAS—skin cancer	4.94e-06	0.0002	CbGpPWpGaD
Imipramine—HTR2C—Signaling by GPCR—NRAS—skin cancer	4.91e-06	0.000199	CbGpPWpGaD
Imipramine—HTR6—Signaling by GPCR—HRAS—skin cancer	4.88e-06	0.000197	CbGpPWpGaD
Imipramine—ADRA1D—Signaling by GPCR—KRAS—skin cancer	4.87e-06	0.000197	CbGpPWpGaD
Imipramine—HTR7—Signaling by GPCR—HRAS—skin cancer	4.87e-06	0.000197	CbGpPWpGaD
Imipramine—ADRA1B—Signaling by GPCR—NRAS—skin cancer	4.7e-06	0.00019	CbGpPWpGaD
Imipramine—HTR6—Signaling by GPCR—IL6—skin cancer	4.67e-06	0.000189	CbGpPWpGaD
Imipramine—HTR7—Signaling by GPCR—IL6—skin cancer	4.66e-06	0.000189	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—BRAF—skin cancer	4.64e-06	0.000188	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—BRAF—skin cancer	4.62e-06	0.000187	CbGpPWpGaD
Imipramine—CHRM4—Signaling by GPCR—HRAS—skin cancer	4.6e-06	0.000186	CbGpPWpGaD
Imipramine—CYP3A7—Metabolism—PTGS2—skin cancer	4.47e-06	0.000181	CbGpPWpGaD
Imipramine—SLC22A2—Metabolism—PTGS2—skin cancer	4.46e-06	0.000181	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—BRAF—skin cancer	4.42e-06	0.000179	CbGpPWpGaD
Imipramine—CHRM5—Signaling by GPCR—HRAS—skin cancer	4.41e-06	0.000178	CbGpPWpGaD
Imipramine—CHRM4—Signaling by GPCR—IL6—skin cancer	4.4e-06	0.000178	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	4.37e-06	0.000177	CbGpPWpGaD
Imipramine—DRD2—Signaling by GPCR—NRAS—skin cancer	4.33e-06	0.000175	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—ENO2—skin cancer	4.31e-06	0.000174	CbGpPWpGaD
Imipramine—HTR2A—Signaling by GPCR—NRAS—skin cancer	4.26e-06	0.000173	CbGpPWpGaD
Imipramine—HRH1—Signaling by GPCR—NRAS—skin cancer	4.25e-06	0.000172	CbGpPWpGaD
Imipramine—HTR1A—Signaling by GPCR—KRAS—skin cancer	4.25e-06	0.000172	CbGpPWpGaD
Imipramine—CHRM1—Signaling by GPCR—NRAS—skin cancer	4.24e-06	0.000172	CbGpPWpGaD
Imipramine—CHRM3—Signaling by GPCR—NRAS—skin cancer	4.23e-06	0.000171	CbGpPWpGaD
Imipramine—HTR2C—Signaling by GPCR—KRAS—skin cancer	4.23e-06	0.000171	CbGpPWpGaD
Imipramine—CHRM5—Signaling by GPCR—IL6—skin cancer	4.22e-06	0.000171	CbGpPWpGaD
Imipramine—CHRM2—Signaling by GPCR—NRAS—skin cancer	4.19e-06	0.00017	CbGpPWpGaD
Imipramine—ADRA1A—Signaling by GPCR—NRAS—skin cancer	4.17e-06	0.000169	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—ERCC2—skin cancer	4.16e-06	0.000169	CbGpPWpGaD
Imipramine—SLC22A1—Metabolism—PTGS2—skin cancer	4.16e-06	0.000168	CbGpPWpGaD
Imipramine—ADRA1D—Signaling by GPCR—HRAS—skin cancer	4.14e-06	0.000168	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—BRAF—skin cancer	4.07e-06	0.000165	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—ERCC2—skin cancer	4.06e-06	0.000164	CbGpPWpGaD
Imipramine—ADRA1B—Signaling by GPCR—KRAS—skin cancer	4.05e-06	0.000164	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—BRAF—skin cancer	4.01e-06	0.000162	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—BRAF—skin cancer	4e-06	0.000162	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—BRAF—skin cancer	3.99e-06	0.000161	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—BRAF—skin cancer	3.97e-06	0.000161	CbGpPWpGaD
Imipramine—ADRA1D—Signaling by GPCR—IL6—skin cancer	3.97e-06	0.000161	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—NRAS—skin cancer	3.94e-06	0.000159	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—BRAF—skin cancer	3.94e-06	0.000159	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—NRAS—skin cancer	3.93e-06	0.000159	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—BRAF—skin cancer	3.92e-06	0.000159	CbGpPWpGaD
Imipramine—CHRM3—Metabolism—PTGS2—skin cancer	3.84e-06	0.000155	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—ERCC2—skin cancer	3.83e-06	0.000155	CbGpPWpGaD
Imipramine—DRD2—Signaling by GPCR—KRAS—skin cancer	3.73e-06	0.000151	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—NRAS—skin cancer	3.72e-06	0.00015	CbGpPWpGaD
Imipramine—HTR2A—Signaling by GPCR—KRAS—skin cancer	3.67e-06	0.000149	CbGpPWpGaD
Imipramine—HRH1—Signaling by GPCR—KRAS—skin cancer	3.66e-06	0.000148	CbGpPWpGaD
Imipramine—CHRM1—Signaling by GPCR—KRAS—skin cancer	3.65e-06	0.000148	CbGpPWpGaD
Imipramine—CHRM3—Signaling by GPCR—KRAS—skin cancer	3.64e-06	0.000147	CbGpPWpGaD
Imipramine—HTR1A—Signaling by GPCR—HRAS—skin cancer	3.61e-06	0.000146	CbGpPWpGaD
Imipramine—CHRM2—Signaling by GPCR—KRAS—skin cancer	3.6e-06	0.000146	CbGpPWpGaD
Imipramine—ADRA1A—Signaling by GPCR—KRAS—skin cancer	3.59e-06	0.000145	CbGpPWpGaD
Imipramine—HTR2C—Signaling by GPCR—HRAS—skin cancer	3.59e-06	0.000145	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—NRAS—skin cancer	3.56e-06	0.000144	CbGpPWpGaD
Imipramine—HTR1A—Signaling by GPCR—IL6—skin cancer	3.46e-06	0.00014	CbGpPWpGaD
Imipramine—ADRA1B—Signaling by GPCR—HRAS—skin cancer	3.44e-06	0.000139	CbGpPWpGaD
Imipramine—HTR2C—Signaling by GPCR—IL6—skin cancer	3.44e-06	0.000139	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—KRAS—skin cancer	3.39e-06	0.000137	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—KRAS—skin cancer	3.39e-06	0.000137	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—NRAS—skin cancer	3.35e-06	0.000135	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—PTGS2—skin cancer	3.3e-06	0.000134	CbGpPWpGaD
Imipramine—ADRA1B—Signaling by GPCR—IL6—skin cancer	3.29e-06	0.000133	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—ERCC2—skin cancer	3.24e-06	0.000131	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—PTGS2—skin cancer	3.23e-06	0.000131	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—KRAS—skin cancer	3.2e-06	0.000129	CbGpPWpGaD
Imipramine—DRD2—Signaling by GPCR—HRAS—skin cancer	3.17e-06	0.000128	CbGpPWpGaD
Imipramine—HTR2A—Signaling by GPCR—HRAS—skin cancer	3.12e-06	0.000126	CbGpPWpGaD
Imipramine—HRH1—Signaling by GPCR—HRAS—skin cancer	3.11e-06	0.000126	CbGpPWpGaD
Imipramine—CHRM1—Signaling by GPCR—HRAS—skin cancer	3.1e-06	0.000126	CbGpPWpGaD
Imipramine—CHRM3—Signaling by GPCR—HRAS—skin cancer	3.09e-06	0.000125	CbGpPWpGaD
Imipramine—CHRM2—Signaling by GPCR—HRAS—skin cancer	3.06e-06	0.000124	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—KRAS—skin cancer	3.06e-06	0.000124	CbGpPWpGaD
Imipramine—ADRA1A—Signaling by GPCR—HRAS—skin cancer	3.05e-06	0.000124	CbGpPWpGaD
Imipramine—DRD2—Signaling by GPCR—IL6—skin cancer	3.03e-06	0.000123	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—TP53—skin cancer	3.01e-06	0.000122	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—TP53—skin cancer	3.01e-06	0.000122	CbGpPWpGaD
Imipramine—HTR2A—Signaling by GPCR—IL6—skin cancer	2.99e-06	0.000121	CbGpPWpGaD
Imipramine—HRH1—Signaling by GPCR—IL6—skin cancer	2.98e-06	0.000121	CbGpPWpGaD
Imipramine—CHRM1—Signaling by GPCR—IL6—skin cancer	2.97e-06	0.00012	CbGpPWpGaD
Imipramine—CHRM3—Signaling by GPCR—IL6—skin cancer	2.96e-06	0.00012	CbGpPWpGaD
Imipramine—CHRM2—Signaling by GPCR—IL6—skin cancer	2.93e-06	0.000119	CbGpPWpGaD
Imipramine—ADRA1A—Signaling by GPCR—IL6—skin cancer	2.92e-06	0.000118	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—NRAS—skin cancer	2.92e-06	0.000118	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—NRAS—skin cancer	2.9e-06	0.000117	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—HRAS—skin cancer	2.88e-06	0.000117	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—KRAS—skin cancer	2.88e-06	0.000117	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—HRAS—skin cancer	2.88e-06	0.000117	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—TP53—skin cancer	2.84e-06	0.000115	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—NRAS—skin cancer	2.78e-06	0.000112	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—IL6—skin cancer	2.76e-06	0.000112	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—IL6—skin cancer	2.75e-06	0.000112	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—TP53—skin cancer	2.72e-06	0.00011	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—HRAS—skin cancer	2.72e-06	0.00011	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—HRAS—skin cancer	2.6e-06	0.000105	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—IL6—skin cancer	2.6e-06	0.000105	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—NRAS—skin cancer	2.56e-06	0.000104	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—TP53—skin cancer	2.56e-06	0.000104	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—NRAS—skin cancer	2.52e-06	0.000102	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—NRAS—skin cancer	2.51e-06	0.000102	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—KRAS—skin cancer	2.51e-06	0.000102	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—NRAS—skin cancer	2.51e-06	0.000101	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—ERCC2—skin cancer	2.5e-06	0.000101	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—NRAS—skin cancer	2.5e-06	0.000101	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—KRAS—skin cancer	2.5e-06	0.000101	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—PTGS2—skin cancer	2.5e-06	0.000101	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—IL6—skin cancer	2.49e-06	0.000101	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—NRAS—skin cancer	2.47e-06	0.0001	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—NRAS—skin cancer	2.47e-06	9.99e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—HRAS—skin cancer	2.45e-06	9.91e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—PTGS2—skin cancer	2.44e-06	9.86e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—KRAS—skin cancer	2.39e-06	9.68e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—IL6—skin cancer	2.34e-06	9.48e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—PTGS2—skin cancer	2.3e-06	9.29e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—TP53—skin cancer	2.23e-06	9.03e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—TP53—skin cancer	2.22e-06	8.98e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—KRAS—skin cancer	2.2e-06	8.92e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—KRAS—skin cancer	2.17e-06	8.78e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—KRAS—skin cancer	2.16e-06	8.76e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—KRAS—skin cancer	2.16e-06	8.73e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—KRAS—skin cancer	2.15e-06	8.7e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—HRAS—skin cancer	2.13e-06	8.64e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—KRAS—skin cancer	2.13e-06	8.62e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—TP53—skin cancer	2.12e-06	8.6e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—KRAS—skin cancer	2.12e-06	8.59e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—HRAS—skin cancer	2.12e-06	8.59e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—IL6—skin cancer	2.04e-06	8.27e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—HRAS—skin cancer	2.03e-06	8.22e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—IL6—skin cancer	2.03e-06	8.22e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—TP53—skin cancer	1.96e-06	7.93e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PTGS2—skin cancer	1.94e-06	7.87e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—IL6—skin cancer	1.94e-06	7.87e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—TP53—skin cancer	1.93e-06	7.8e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—TP53—skin cancer	1.92e-06	7.78e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—TP53—skin cancer	1.92e-06	7.76e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—TP53—skin cancer	1.91e-06	7.73e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—TP53—skin cancer	1.89e-06	7.66e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—TP53—skin cancer	1.89e-06	7.64e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—HRAS—skin cancer	1.87e-06	7.58e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—HRAS—skin cancer	1.84e-06	7.46e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—HRAS—skin cancer	1.84e-06	7.44e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—HRAS—skin cancer	1.83e-06	7.42e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—HRAS—skin cancer	1.83e-06	7.4e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—HRAS—skin cancer	1.81e-06	7.33e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—HRAS—skin cancer	1.8e-06	7.31e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—IL6—skin cancer	1.79e-06	7.26e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—IL6—skin cancer	1.76e-06	7.14e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—IL6—skin cancer	1.76e-06	7.13e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—IL6—skin cancer	1.75e-06	7.1e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—IL6—skin cancer	1.75e-06	7.08e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—IL6—skin cancer	1.73e-06	7.01e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—IL6—skin cancer	1.73e-06	6.99e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PTGS2—skin cancer	1.5e-06	6.08e-05	CbGpPWpGaD
